Scholars Central

Review articlePublished 16 Jun 2017

Harnessing the Immune Regulatory Balance of Toll-like Receptor 9 Agonists in Cancer Immunotherapy.

Authors: Cui J, Bai L, Zhou L, Chen W, Chen J

Immunology Case Reports

Volume 1 · Issue 2 · Pages 20–26

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Toll-like receptor 9 (TLR9), a naturally existing immune regulatory site, not only takes part in enhancing anti-tumor immunity but also promoting the immunosuppressive environment of the growing tumor. TLR9 has shown its potential activity as a therapeutic target in cancer immunotherapy. However, the increased pro-tumor inflammation mediated by TLR9 should also be considered. Therefore, it is important to develop a better understanding of its regulatory mechanisms to improve the therapeutic efficacy. This review will discuss the mechanisms of immune homeostasis regulated by TLR9 signaling pathways, and also introduce the strategies of how to harness the immune regulatory balance by TLR9 agonists, CpG oligodeoxynucleotides, in cancer immunotherapies.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Immunology Case Reports.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalImmunology Case Reports
  • SubjectImmunology & Microbiology
  • BylineArticles whose byline prints “Cui J”
  • BylineArticles whose byline prints “Bai L”
  • BylineArticles whose byline prints “Zhou L”
  • BylineArticles whose byline prints “Chen W”
  • BylineArticles whose byline prints “Chen J”